Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis.
Długosz-Danecka M, Jurczak W, Łątka-Cabała E, Morawska M, Gawroński K, Wiśniewska A, Dudziński M, Wąsik-Szczepanek E, Chmielowska E, Łabędź A, Wdowiak K, Hus I. Długosz-Danecka M, et al. Pol Arch Intern Med. 2018 Aug 31;128(7-8):421-426. doi: 10.20452/pamw.4294. Epub 2018 Jul 11. Pol Arch Intern Med. 2018. PMID: 30057377 Free article.
Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles.
Długosz-Danecka M, Szmit S, Kocurek A, Koźlik P, Giza A, Zimowska-Curyło D, Małkowski B, Sowa-Staszczak A, Kużdżał J, Jurczak W. Długosz-Danecka M, et al. Pol Arch Intern Med. 2019 Apr 30;129(4):259-266. doi: 10.20452/pamw.14786. Epub 2019 Apr 4. Pol Arch Intern Med. 2019. PMID: 30945698 Free article.
Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.
Wołowiec D, Szymczyk A, Potoczek S, Krochmalczyk D, Zawirska D, Piotrowska M, Malenda A, Soroka-Wojtaszko M, Kopacz A, Wąsik-Szczepanek E, Graboś-Michalak J, Raźny M, Wichary R, Bramowicz-Jarosz B, Seweryn M, Długosz-Danecka M, Hus I. Wołowiec D, et al. Chemotherapy. 2019;64(3):155-162. doi: 10.1159/000503220. Epub 2019 Nov 12. Chemotherapy. 2019. PMID: 31715597
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M, Hus I, Puła B, Jurczyszyn A, Chojnacki T, Blajer-Olszewska B, Drozd-Sokołowska J, Raźny M, Romejko-Jarosińska J, Taszner M, Jurczak W. Długosz-Danecka M, et al. Pharmacol Rep. 2019 Jun;71(3):473-477. doi: 10.1016/j.pharep.2019.02.001. Epub 2019 Feb 6. Pharmacol Rep. 2019. PMID: 31003160
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, Szymczyk A, Hus M, Szeremet A, Drozd-Sokolowska J, Waszczuk-Gajda A, Zaucha JM, Holojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Osowiecki M, Knopinska-Posluszny W, Dudzinski M, Zawirska D, Subocz E, Halka J, Pluta A, Wichary R, Kumiega B, Budziszewska BK, Jurczak W, Lech-Maranda E, Giannopoulos K, Robak T, Jamroziak K. Pula B, et al. Anticancer Res. 2020 Jul;40(7):4059-4066. doi: 10.21873/anticanres.14403. Anticancer Res. 2020. PMID: 32620653
Rituximab biosimilars in clinical practice.
Jurczak W, Długosz-Danecka M. Jurczak W, et al. Leuk Lymphoma. 2020 Jul;61(7):1523-1524. doi: 10.1080/10428194.2020.1788016. Epub 2020 Jul 6. Leuk Lymphoma. 2020. PMID: 32628057 No abstract available.
47 results